Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Distribution agreements for Matritech's cancer test:

This article was originally published in Clinica

Executive Summary

Matritech has formed two marketing agreements for NMP22, its bladder cancer test, with Finnish company Wallac's German subsidiary and an unnamed Italian company. Matritech expects to release details concerning the Italian distributor by the end of the month. A distribution agreement with Boehringer Ingelheim, which was struck in 1994 (see Clinica No 617, p13), has been terminated by mutual consent, Matritech says. The test kit is an EIA to measure the amount of NMP in stabilised urine (see Clinica No 704, p 17).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts